NO20082699L - Immunoglobuliner - Google Patents

Immunoglobuliner

Info

Publication number
NO20082699L
NO20082699L NO20082699A NO20082699A NO20082699L NO 20082699 L NO20082699 L NO 20082699L NO 20082699 A NO20082699 A NO 20082699A NO 20082699 A NO20082699 A NO 20082699A NO 20082699 L NO20082699 L NO 20082699L
Authority
NO
Norway
Prior art keywords
immunoglobulins
antibodies
disorders
nogo
prevention
Prior art date
Application number
NO20082699A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Paul A Hamblin
Volker Germaschewski
Ruth Mcadam
Rabinder Kumar Prinjha
Stepanie Jane Clegg
George Kopsidas
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082699(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20082699L publication Critical patent/NO20082699L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse angår antistoffer til NOGO, farmasøytiske formuleringer inneholdende dem og anvendelse av slike antistoffer for behandling og/eller forebygging av nevrologiske sykdommer/lidelser.
NO20082699A 2005-12-16 2008-06-11 Immunoglobuliner NO20082699L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (1)

Publication Number Publication Date
NO20082699L true NO20082699L (no) 2008-09-08

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082699A NO20082699L (no) 2005-12-16 2008-06-11 Immunoglobuliner

Country Status (31)

Country Link
US (2) US8362208B2 (no)
EP (2) EP2228391A3 (no)
JP (1) JP5015949B2 (no)
KR (1) KR101355118B1 (no)
CN (1) CN101374863B (no)
AR (1) AR057239A1 (no)
AU (1) AU2006325228B2 (no)
BR (1) BRPI0619855A2 (no)
CA (1) CA2633501C (no)
CR (1) CR10099A (no)
CY (1) CY1113094T1 (no)
DK (1) DK1960429T3 (no)
EA (1) EA015536B1 (no)
ES (1) ES2389380T3 (no)
GB (1) GB0525662D0 (no)
HK (1) HK1119720A1 (no)
HR (1) HRP20120684T1 (no)
IL (1) IL192086A0 (no)
JO (1) JO2795B1 (no)
MA (1) MA30041B1 (no)
MY (1) MY149492A (no)
NO (1) NO20082699L (no)
NZ (1) NZ569143A (no)
PE (1) PE20071099A1 (no)
PL (1) PL1960429T3 (no)
PT (1) PT1960429E (no)
SI (1) SI1960429T1 (no)
TW (1) TWI378940B (no)
UA (1) UA96279C2 (no)
WO (1) WO2007068750A2 (no)
ZA (2) ZA200805111B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
EP2252631B1 (en) 2008-04-02 2016-04-13 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
JP2011522792A (ja) 2008-05-06 2011-08-04 グラクソ グループ リミテッド 生物活性薬の封入
CA2730473A1 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
BR112014032987A2 (pt) 2012-07-05 2017-06-27 Glaxo Group Ltd método de tratamento ou profilaxia de um distúrbio neurológico
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
EP4048692A2 (en) 2019-10-24 2022-08-31 NovaGo Therapeutics AG Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
EP4355782A1 (en) 2021-06-17 2024-04-24 Petmedix Ltd. Anti canine cd20 antibodies
WO2023067358A1 (en) 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2023152486A1 (en) 2022-02-09 2023-08-17 Petmedix Ltd Therapeutic antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
HU226535B1 (en) 1994-05-27 2009-03-30 Glaxosmithkline Spa Quinoline derivatives as tachykinin nk3 receptor antagonists, pharmaceutical compositions containing them, and their use
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
EP0835127B1 (en) 1995-06-27 2004-09-08 Research Foundation of Cuny, Hunter College Composition containing a myelin-associated glycoprotein (mag) inhibitor which comprises an altered or mutated form of mag
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DK1098972T3 (da) 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
AU774367C (en) 1998-11-06 2005-04-21 University Of Zurich Nucleotide and protein sequences of nogo genes and methods based thereon
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
PL1711530T3 (pl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych
EP2990053A1 (en) * 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
AU2006325228B2 (en) 2011-12-15
EP2228391A2 (en) 2010-09-15
EA015536B1 (ru) 2011-08-30
HRP20120684T1 (hr) 2012-09-30
PL1960429T3 (pl) 2012-11-30
DK1960429T3 (da) 2012-09-24
CY1113094T1 (el) 2016-04-13
MA30041B1 (fr) 2008-12-01
SI1960429T1 (sl) 2012-09-28
JP5015949B2 (ja) 2012-09-05
PT1960429E (pt) 2012-09-25
WO2007068750A2 (en) 2007-06-21
EP1960429B1 (en) 2012-06-27
ES2389380T3 (es) 2012-10-25
MY149492A (en) 2013-09-13
JP2009519025A (ja) 2009-05-14
EA200801343A1 (ru) 2008-12-30
CN101374863A (zh) 2009-02-25
NZ569143A (en) 2011-08-26
AU2006325228A1 (en) 2007-06-21
EP2228391A3 (en) 2010-12-29
IL192086A0 (en) 2008-12-29
US20100221260A1 (en) 2010-09-02
AR057239A1 (es) 2007-11-21
CR10099A (es) 2008-09-22
CA2633501A1 (en) 2007-06-21
WO2007068750A3 (en) 2007-11-29
CA2633501C (en) 2015-03-31
BRPI0619855A2 (pt) 2011-10-25
ZA200906162B (en) 2010-05-26
PE20071099A1 (es) 2007-11-22
HK1119720A1 (en) 2009-03-13
US20130287781A1 (en) 2013-10-31
KR101355118B1 (ko) 2014-02-06
CN101374863B (zh) 2013-05-29
KR20080080644A (ko) 2008-09-04
TWI378940B (en) 2012-12-11
JO2795B1 (en) 2014-03-15
GB0525662D0 (en) 2006-01-25
ZA200805111B (en) 2009-12-30
UA96279C2 (ru) 2011-10-25
US8362208B2 (en) 2013-01-29
TW200801038A (en) 2008-01-01
EP1960429A2 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
NO20082699L (no) Immunoglobuliner
NO20062767L (no) Immunoglobuliner
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20045323L (no) Antistoffer
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
MX2009006891A (es) Anticuerpos cd44.
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200709817A (en) Platform antibody compositions
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2006058869A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
NO20076663L (no) Immunoglobuliner
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
NO20083045L (no) Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkomplekset
WO2009051661A3 (en) Substituted aryl alkylamino-oxy-analogs and uses thereof
NO20076387L (no) Anvendelse av IL-18BP isoformer til behandling og/eller forhindring av neurologiske inflammatoriske sykdommer
TW200716602A (en) Novel compounds
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application